**Name of journal: *World Journal of Clinical Infectious Diseases***

**ESPS Manuscript NO: 16405**

**Manuscript Type: Review**

**Epidemiological perspective of drug resistant extrapulmonary tuberculosis**

Singh PK *et al*. Drug resistant extrapulmonary tuberculosis

**Pravin Kumar Singh, Amita Jain**

**Pravin Kumar Singh, Amita Jain,** Department of Microbiology, King George’s Medical University, Lucknow (UP) 226003, India

**Author contributions:** Both the authors collected the relevant information and wrote the paper.

**Conflict-of-interest statement:** Pravin Kumar Singh is employed by Foundation for Innovative New Diagnostic, however author alone is responsible for the views expressed in this paper.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Amita Jain, Professor,** Department of Microbiology, King George’s Medical University, Shah Mina Road, Chowk, Lucknow (UP) 226003, India. amita602002@yahoo.com

**Telephone:** +91-522-2258633

**Fax:** +91-522-2258633

**Received:** January 15, 2015

**Peer-review started:** January 16, 2015

**First decision:** March 20, 2015

**Revised:** August 11, 2015

**Accepted:** September 7, 2015

**Article in press:**

**Published online:**

**Abstract**

Tuberculosis (TB) remains one of the leading infectious diseases causing significant morbidity and mortality worldwide. Although, pulmonary TB is the most common presentation and is the main transmissible form of the disease, extrapulmonary TB also significantly contributes to the burden of disease and can cause severe complications and disabilities. At present, the most serious issue with TB control programme is emergence of multi and extensively drug resistant *Mycobacterium tuberculosis* strain world-wide. As the number of drug resistant pulmonary TB is increasing around the world, the number of drug resistant TB with extrapulmonary manifestations are also on rise. However, there is surprisingly scant information in medical literatures on prevalence and impact of extrapulmonary drug-resistant TB. Here, we appraise the recent epidemiological studies that underpin the status and impact of drug resistance in TB cases with extrapulmonary manifestations.

**Key words:** Tuberculosis; Extrapulmonary tuberculosis; Drug resistance; *Mycobacterium tuberculosis*; Epidemiology

© **The Author(s) 2015**. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The emergence of highly drug resistant (DR) *Mycobacterium tuberculosis* and human immunodeficiency virus epidemic has paved the way for resurgence of tuberculosis (TB). Extrapulmonary tuberculosis (EPTB), accounts for a significant proportion of all notified TB cases, is a persistent global health issue. Although DR-EPTB is uncommon, but the increasing rate of DR-pulmonary TB around the world has heightened our concern for DR-EPTB too. Unfortunately, systematic surveillance data on DR-EPTB is lacking, however, sporadic information from different countries has begun to accumulate. Here, we aim to provide current understanding on epidemiological scenario of DR-EPTB and also to address some of the key challenges associated with diagnosis, control and management of DR-EPTB.

Singh PK, Jain A. Epidemiological perspective of drug resistant extrapulmonary tuberculosis. *World J Clin Infect Dis* 2015; In press

**INTRODUCTION**

Despite the availability of effective treatment for many decades, tuberculosis (TB) remains an enormous global health problem, responsible for about 1.5 million deaths annually[1]. *Mycobacterium tuberculosis*, the causative agent, usually affects the lungs [pulmonary TB (PTB)], however it may spread through lymphatic or hematogenous dissemination to virtually any organs and tissues of body resulting in the development of extrapulmonary TB (EPTB). In last few decades, extensive information has been gathered describing the clinical pictures of different common and rare forms of EPTB. The distribution of various types of EPTB may vary among different populations and countries. However, the most common sites of EPTB includes peripheral lymph nodes, pleura, genitourinary sites, bones and joints, abdomen (peritoneum and gastrointestinal tract), and the central nervous system[2,3]. A detailed discussion on clinical aspect of each form of EPTB is beyond the scope of this review but can be found elsewhere[2,3].

The existence of EPTB is centuries old however the prime attention of global TB control programme has been principally focused on contagious pulmonary TB. Indeed, EPTB is milder and less contagious as compared to PTB it cannot be overlooked as it constitutes about 20% of all form of TB among immuno-competent adults[2]. Moreover, EPTB result in significant morbidity and mortality dependent on the organs affected (like central nervous system) and also due to various difficulties encountered in achieving a timely and definite diagnosis[4]. EPTB became more common world-wide since the advent of human immunodeficiency virus (HIV) infection. Consequently, a significantly high predisposition to the development of EPTB can be found in patients with concurrent AIDS and TB[3]. Younger age is another potential risk factor for developing EPTB and even some aggressive form of TB like tubercular meningitis or miliary TB are commonly reported in children[5,6]. Such mounting significance of EPTB is suggestive to consider EPTB as much a public health priority as pulmonary TB (Table 1).

At present, the global emergence of multi-drug resistant (MDR) and even extensively drug resistant (XDR) TB is a great challenge to success of global TB control efforts. MDR-TB is usually caused by spontaneous genetic mutation in *Mycobacterium tuberculosis* (*M. tuberculosis)* that confers resistance to the two main first line antimicrobials rifampicin (RIF) and isoniazid (INH). Mutation in a hotspot region (81-bp) of *rpoB* gene (encoding beta-subunit of DNA dependent RNA polymerase) is responsible for rifampicin resistance while INH resistance is largely conferred by mutations in *katG* gene and *inhA* gene[7]. When MDR *M. tuberculosis* develops additional resistance to a fluroquinolone and a second line injectable drug (*i.e.* amikacin, kanamycin or capreomycin), it is termed as XDR. Although, drug resistance in PTB has been extensively studied on various aspects, status of drug resistant (DR) EPTB is not clear. While some presentations of EPTB may be life threatening, the involvement of drug resistant *M. tuberculosis* strain may amplify the risk of morality. Thus, in the present era of HIV pandemic coupled with global emergence of MDR and XDR *M. tuberculosis*, DR-EPTB represents as a real and new significant challenge to public health that is yet to receive serious attention. In this review, we aim to provide an epidemiological overview of drug resistant EPTB and to discuss some of key challenges associated with diagnosis and control of disease.

**EPIDEMIOLOGICAL SCENARIO**

As many population based TB surveys of different countries are more confined to smear positive PTB especially in adult populations, the knowledge of the global epidemiology of EPTB is rather limited. Despite this, surveys from different parts of world have accumulated that demonstrate substantial increase of global burden of EPTB in both developed and developing countries, particularly in regions where the prevalence of HIV infection is high. In the areas where adequate diagnostic and reporting systems are available, EPTB accounts for 20%-25% of reported cases[8].Recentestimate of WHO showed that among 5.4 million new TB cases, 0.8 million had EPTB of which a significant proportion (about 70%) were localized into Southeast and African regions[1]. In developed countries, 10%-15% of TB cases have extra-pulmonary involvement, but this rate is much higher in patients belonging to high TB burden countries[3]. India ranks first in having maximum number (about 0.35 million) of EPTB among new cases[1]. The successful TB control program in many developed countries resulted into a declining trend of incidence of pulmonary TB; however the rate of EPTB has remained constant or increased substantially. In USA, EPTB ratio has increased from 8% to 17.5% during year 1964 to 1986[9]. Similarly, an increase in prevalence of EPTB had been reported as 21% in Western Europe and 10% in Eastern Europe[10]. Recently, the incidence of EPTB is reported as 22% and about 50% of all diagnosed TB cases in USA and UK, respectively[11,12].

Unlike pulmonary TB, systematic drug resistant surveillance for EPTB has not been conducted. Furthermore, drug susceptibility testing for EPTB is not routinely undertaken in many resource-limited countries, thus no authentic estimates on prevalence of drug resistant EPTB could be made available. However, sporadic information mostly derived either from retrospective cohort studies or TB surveillance data is now available from different parts of world and is summarized in Table 2. As per data accrued thus from different countries, the prevalence of MDR may lie between 1%-69% of total of EPTB cases; whereas, the proportion of resistant cases to any one anti-tuberculosis drug is about 10%-75% (Table 2). The wide variation in proportion of drug resistant EPTB among different studies is probably due to variation in study settings, burden of MDR-TB and quality of medical services in particular region, demographic characteristic and HIV status of patients, types of EPTB cases investigated, sample size and its selection criteria *etc*. The comprehensive public health surveillance data of USA showed that about only 1% of total EPTB cases studied during 1993-2006 were MDR-EPTB[13]. On the other hand, some studies were published from high TB burden countries with much higher rate of DR-EPTB (Table 2). However in most of these studies data were collected from a cohort in a specific programmatic setting, mostly tertiary health care facility/hospitals that serves underprivileged population. In addition to this, the prevalence estimates in most of the tabulated studies collected from only a subset cases *i.e.*, culture confirmed EPTB cases. Looking at these potential limitations the prevalence figures may not be truly representative to that particular region or country; nonetheless, these studies are definitely concerning. Further, it is worth-while to note that the deadly combination of drug resistance among cases of TBM has been reported increasingly in many countries (Table 2). Recently, the rare possibility for the presence of XDR strain in extraplumonary site has also been documented in India[14].

Although, the behavior of the mycobacterium does not differ from site to site, drug resistance including MDR-TB is less common in cases of EPTB as compared to PTB. Studies from different countries have compared the drug resistance profiles between *Mycobacterium tuberculosis* (MTB) isolates recovered from pulmonary and extra-pulmonary sites and showed negative association of EPTB with anti-TB drug resistance[14-17]. This is due to the fact that the selective multiplication of resistant mutants of *M. tuberculosis* in caseous focal lesions of extrapulmonary sites is much less than in cavitary lesions of pulmonary sites. The development of DR-EPTB is mainly acquired through previous improper anti-tuberculosis regimen, poor patient compliance, a prolonged diagnosis of drug resistance and the spreading of drug-resistant strains. Drug resistance in EPTB is more common in previously treated patients[18]. Recently, a high level drug resistance among treatment failure PTB (48.1%) and EPTB cases (52.7%) from north India was reported[19]. Similarly, in another study, about 73% patients with drug resistant TBM had a history of prior exposure to anti-tuberculosis drugs[20].

The heterogeneous nature of extrapulmonary samples is another factor that not only contributes the variability in sensitivity values of various diagnostics but may also contribute to variation in drug resistance profile. In a study conducted in Taiwan, drug resistance profile of *M. tuberculosis* isolates in specimens derived from various extrapulmonary sites was compared. In this study, isoniazid-resistant (or resistant to any first line drugs) *M. tuberculosis* was more common in genitourinary and pleural sites followed by skin and soft tissue, peritoneum and lymphnode[17]. Cerebrospinal fluid, a preferred sample for diagnosis of TBM was not included in this study but drug resistance among TBM cases have been reported relatively high in different countries. Different Indian studies investigated the cerebrospinal fluid (CSF) collected from the cases of TBM and a high prevalence of drug resistant strain (MDR: about 2%; Resistance to any one first line drugs: 18%-33%) were found. Previous studies from different parts of the world showed a predominant resistance to isoniazid (INH) in EPTB cases especially in TBM[17,21-23]. Among the first line drugs, INH is the only bactericidal agent that easily crosses the blood-brain barrier and is known to penetrate freely into the CSF. Therefore, INH resistance is a potential threat to the successful treatment and causes significant mortality in EPTB especially when meningeal involvement is present[24,25].

EPTB is more common in HIV infected individuals and it may be undiagnosed until advance stages of the disease[26]. In addition to this, recently it is found that HIV status may also influence the incidence of drug resistance among cases of EPTB especially in TBM. Studies from Vietnam demonstrated that a significantly higher proportion (> 50%) of CSF mycobacterial isolates from TBM patients were resistant to one or more first-line anti-tuberculous drugs[27,28]. In contrast, no significant association between HIV infection and drug resistance among TBM cases were seen in some other studies[21,24].

Recent studies suggest that different lineages of *M.tuberculosis* may have different clinical manifestation. Indo-Oceanic and East-African Indian lineages were associated with exclusively extrapulmonary tuberculosis disease[29]. Interestingly, a strong association between “Beijing genotype” lineage, drug resistance, and HIV infection in a cohort of TBM patients has been shown[28]. Similarly, a Russian study also observed prominent association of Beijing genotype with multi-drug resistance (out of 80 Beijing genotype isolates, 90.5% were multi-drug resistant) in cases of tuberculous spondylitis[30]. However, it seems that such association may be influenced by variable distributions of *M. tuberculosis* lineages in different parts of world. Despite this possibility, the Beijing family of *M. tuberculosis* is considered highly virulent and associated with drug resistance in several settings[31,32].

**CHALLENGES IN DIAGNOSIS, TREATMENT AND MANAGEMENT**

Respiratory tract infections caused by pathogens other than *Mycobacteria* isoften implicated by physician. But the treatment failure and recurrence or persistence of symptoms led to suspicion and investigation of PTB. Despite this initial delay, the definite diagnosis and effective treatment management of PTB is feasible. Unlike PTB, the diagnosis of EPTB is a major challenge for clinician. As the clinical manifestation of EPTB is highly heterogeneous, many of patients are examined by different specialists with little awareness in TB diagnosis thus may cause significant delay in including the EPTB into differential diagnosis panel. Data from many countries shows that 20%-50% cases of EPTB are diagnosed post-mortem[33]; which not only highlights our limited ability to diagnose the EPTB but also provide a possible reason for lower incidence of EPTB in many countries. Lack of strong laboratory backup at peripheral health facility level in many high TB burden countries also contribute significantly for excess delay and difficulty to establish EPTB.

It is believed that a small amount of tubercle bacilli even sensitive to anti-tubercular drugs often cause great damage in some aggressive form of TB like TBM. Therefore, diagnostic delay in EPTB poses great risk of mortality. Previous studies demonstrated, a delay of 3 d between TBM presentation and initiation of anti-tuberculous therapy among pediatric as well as adult cases is associated with increased risk of death[34,35]. Further, drug resistance may severely complicate the situation because a twofold increase in mortality was observed recently among the isoniazid drug resistant TBM cases[36]. The various hurdles making the diagnosis of DR-EPTB an issue are highlighted in Table 3.

Although, EPTB is not considered as contagious but concomitant contagious PTB may spread the infection to others. European TB surveillance report[37] showed that about 1/4th of all EPTB cases had also pulmonary involvement. Thus the presence of EPTB does not exclude the pulmonary involvement, even though such cases are nevertheless classified as contagious PTB[1]. Recent studies have found that even with a normal chest radiograph, the concomitant pulmonary involvement may be present in considerable proportion (up to 18%) of patients[38,39]. However still in routine practice, the existence of PTB in cases of EPTB is not generally ruled out.

For a definite diagnosis of EPTB, WHO recommends that it should be on the basis of culture-positive specimen and/or positive histology and/or strong clinical evidence consistent with active EPTB[1]. A cautious investigation of clinical, radiological and histopathological representations in different form of EPTB may provide some clues to achieve the diagnosis even than seeking the laboratory based diagnosis is important to establish the disease. Although laboratory testing for EPTB follows the same principles as for PTB, but it is very difficult and negative test result does not rule out the EPTB.

The multiplication of tubercle bacilli is generally hindered within the caseous foci lesion/tissues of extrapulomnary sites due to low availability of oxygen as well as acidic pH, and the presence of toxic fatty acids[40]. Therefore under these stress condition, EPTB is generally found in pauci-bacillary that may be skipped to be detected by conventional diagnostic tests. Direct visualization of acid-fast bacteria is still the first and most preferred microbiological test but it is far from being sensitive to diagnose EPTB[41]. At present, microbiological confirmation (either by solid or liquid culture method) of *M. tuberculosis* in samples from the affected sites of EPTB is considered as gold standard which also gives the opportunity to identify the *Mycobacterium* species and to perform phenotypic drug-susceptibility tests as well as genotyping for molecular epidemiology studies. However, the main drawback of culture is long turn-around time and compromised sensitivity due to lower and non-uniform distribution of bacillary load at extrapulmonary sites as well as compromised quality and quantity of specimen. It has been demonstrated that concentration of large volumes of sampled fluid (CSF, ascites, *etc*.) and repeated analyses can increase the diagnostic yield[42] however, it is often too difficult to get additional and adequate amount of samples from the patients.

As discussed above, delay in diagnosis may not be acceptable in the management of aggressive TB cases like TBM or HIV-associated EPTB, a rapid and sensitive diagnosis and DST method is always pre-requisite. In the same regard, several nucleic-acid amplification tests (NAAT) are now available that can detect *M. tuberculosis* and can also determine the drug resistance to some key drugs. Of the various NAAT, Xpert MTB/RIF seems most promising as it is fully automated cartridge-based real-time PCR based test that efficiently detects both TB and resistance to rifampicin in less than 2 h. WHO reviewed a set of studies and concluded into an excellent sensitivity and specificity of Xpert MTB/RIF from pooled data on samples collected from various extrapulmonary sites (CSFs, gastric fluids and biopsies)[43]. Unfortunately, this system does not determine the isoniazid resistance which is known to be significantly associated with mortality among TBM cases. The cost of the test, dependency on electric supply, the cartridge supply and storage conditions and the difficulty to carry and implement the system in limited resource settings are some other challenges. Nevertheless, Xpert MTB/RIF assay coupled with its speed, simplicity and less biohazard problems could play an important routine role in diagnosis of EPTB.

Like diagnosis, the treatment and management of EPTB is also full of challenges and recently a meta-analysis showed that treatment outcomes were poor in patients with DR-TB[44]. This is especially due to poor drug penetration to the affected tissue and the lack of accessibility of tissue/sample for assessing the treatment response by serial cultures. Further, any degree of drug resistance hinders the treatment and may results into poor outcomes especially in severe form of disease. The problem gets compounded among HIV infected individual as it has been shown that multidrug-resistant tuberculosis at treatment initiation, positive human immunodeficiency virus status among EPTB cases are significantly associated with mortality[24,45]. WHO recommended the treatment of MDR-EPTB with the same strategy involving the same regimen and duration as pulmonary MDR-TB. However in severe complication, individualized chemotherapy and some other means like surgery, adjunctive corticosteroids, immune-modulators may result into good treatment outcomes[46,47]. Owing to increasing incidence of drug resistance and severity of some kinds of EPTB, there is an urgent need for effective short-term regimens with newer drugs having better penetration at various sites in body.

At programmatic management level, EPTB also deserves special attention to ensure access of quality diagnosis, drug susceptibility testing and prompt initiation of appropriate therapy. The political commitment and support in this regard is utmost important. In many high TB burden countries, the peripheral health centers are still devoid of strong laboratory back-up and sensitized medical staff. In India, EPTB is predominantly managed in the private sector and these cases are rarely notified to government agencies. Additionally, in private sector the diagnostic and treatment practices is not firmly followed as per national or international standards and usually treatment is started without having culture confirmation and drug susceptibility testing[48]. Taking all these challenges into consideration, it is anticipated that MDR-TB affecting extrapulmonary site may continue to increase.

**CONCLUSION**

Drug resistance among cases of EPTB is a definitely rising problem in most of the countries where ever it has been investigated. Since survey study on similar line begun to accumulate only recently, a continued effort in future will be of exquisite importance to achieve reliable estimates of the incidence in different parts of world. Such information will be imperative in establishment of strategic frameworksfor intensified cases finding, effective treatment management and also to garner the resources necessary for the prevention of associated high morbidity and mortality. Further, there is an urgent need for increasing awareness of the clinician to rising incidence drug resistant EPTB and to consider the drug resistance testing before start of therapy for better treatment outcomes. We hope this preliminary review will encourage the future systematic studies to precisely define the epidemiological picture of drug-resistance EPTB.

**REFERENCES**

1 **World Health Organization**. Global Tuberculosis Report 2013. Geneva: WHO, 2013. [accessed 2015 Jan 5]. Available from: URL: http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656\_eng.pdf

2 **Sharma SK**, Mohan A. Extrapulmonary tuberculosis. *Indian J Med Res* 2004; **120**: 316-353 [PMID: 15520485]

3 **Golden MP**, Vikram HR. Extrapulmonary tuberculosis: an overview. *Am Fam Physician* 2005; **72**: 1761-1768 [PMID: 16300038]

4 **Rossato Silva D**, Müller AM, Dalcin Pde T. Factors associated with delayed diagnosis of tuberculosis in hospitalized patients in a high TB and HIV burden setting: a cross-sectional study. *BMC Infect Dis* 2012; **12**: 57 [PMID: 22420509 DOI: 10.1186/1471-2334-12-57]

5 **Nelson LJ**, Wells CD. Global epidemiology of childhood tuberculosis. *Int J Tuberc Lung Dis* 2004; **8**: 636-647 [PMID: 15137548]

6 **Carrol ED**, Clark JE, Cant AJ. Non-pulmonary tuberculosis. *Paediatr Respir Rev* 2001; **2**: 113-119 [PMID: 12531057 DOI: 10.1053/prrv.2000.0118]

7 **Zhang Y**, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. *Int J Tuberc Lung Dis* 2009; **13**: 1320-1330 [PMID: 19861002]

8 **World Health Organization**. Treatment of tuberculosis: Guidelines. 4th ed. Available from: URL: http://apps.who.int/iris/bitstream/10665/44165/1/9789241547833\_eng.pdf

9 **Gonzalez OY**, Adams G, Teeter LD, Bui TT, Musser JM, Graviss EA. Extra-pulmonary manifestations in a large metropolitan area with a low incidence of tuberculosis. *Int J Tuberc Lung Dis* 2003; **7**: 1178-1185 [PMID: 14677893]

10 **Euro TB**. (InVS/KNCV) and the national coordinators for tuberculosis surveillance in the WHO European Region. Surveillance of tuberculosis in Europe. Report on tuberculosis cases notified in 1998. 2001. [accessed 2015 Jan 5]. Available from: URL: http://opac.invs.sante.fr/doc\_num.php?explnum\_id=5656

11**Centers for Disease Control and Prevention.** Reported Tuberculosis in the United States, 2010. Atlanta, GA: CDC, 2011

12 **Health Protection Agency**. Tuberculosis in the UK: Annual report on tuberculosis surveillance in the UK, 2012. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment\_data/file/332560/TB\_Annual\_Report\_2012.pdf

13 **Peto HM**, Pratt RH, Harrington TA, LoBue PA, Armstrong LR. Epidemiology of extrapulmonary tuberculosis in the United States, 1993-2006. *Clin Infect Dis* 2009; **49**: 1350-1357 [PMID: 19793000 DOI: 10.1086/605559]

14 **Balaji V**, Daley P, Anand AA, Sudarsanam T, Michael JS, Sahni RD, Chordia P, George IA, Thomas K, Ganesh A, John KR, Mathai D. Risk factors for MDR and XDR-TB in a tertiary referral hospital in India. *PLoS One* 2010; **5**: e9527 [PMID: 20209106 DOI: 10.1371/journal.pone.0009527]

15 **Baumann MH**, Nolan R, Petrini M, Lee YC, Light RW, Schneider E. Pleural tuberculosis in the United States: incidence and drug resistance. *Chest* 2007; **131**: 1125-1132 [PMID: 17426219 DOI: 10.1378/chest.06-2352]

16 **Robert J**, Trystram D, Truffot-Pernot C, Jarlier V. Multidrug-resistant tuberculosis: eight years of surveillance in France. *Eur Respir J* 2003; **22**: 833-837 [PMID: 14621093 DOI: 10.1183/09031936.03.00014103]

17 **Lai CC**, Liu WL, Tan CK, Huang YC, Chung KP, Lee MR, Hsueh PR. Differences in drug resistance profiles of Mycobacterium tuberculosis isolates causing pulmonary and extrapulmonary tuberculosis in a medical centre in Taiwan, 2000-2010. *Int J Antimicrob Agents* 2011; **38**: 125-129 [PMID: 21592735 DOI: 10.1016/j.ijantimicag.2011.03.016]

18 **Maurya AK**, Kant S, Nag VL, Kushwaha R, Dhole TN. Detection of 123 bp fragment of insertion element IS6110 Mycobacterium tuberculosis for diagnosis of extrapulmonary tuberculosis. *Indian J Med Microbiol* 2012; **30**: 182-186 [PMID: 22664434 DOI: 10.4103/0255-0857.96688]

19 **Sethi S**, Biswal M, Chatterjee SS, Mewara A, Gupta D, Kumar S, Sharma M. Susceptibility pattern among pulmonary and extrapulmonary isolates of Mycobacterium tuberculosis in north India. *African J Microbiol Res* 2012; **6**: 3696-3699

20 **Patel VB**, Padayatchi N, Bhigjee AI, Allen J, Bhagwan B, Moodley AA, Mthiyane T. Multidrug-resistant tuberculous meningitis in KwaZulu-Natal, South Africa. *Clin Infect Dis* 2004; **38**: 851-856 [PMID: 14999630]

21 **Vinnard C**, Winston CA, Wileyto EP, MacGregor RR, Bisson GP. Isoniazid-resistant tuberculous meningitis, United States, 1993-2005. *Emerg Infect Dis* 2011; **17**: 539-542 [PMID: 21392454 DOI: 10.3201/eid1703.101715]

22 **Venkataswamy MM**, Rafi W, Nagarathna S, Ravi V, Chandramuki A. Comparative evaluation of BACTEC 460TB system and Lowenstein-Jensen medium for the isolation of M. tuberculosis from cerebrospinal fluid samples of tuberculous meningitis patients. *Indian J Med Microbiol* 2007; **25**: 236-240 [PMID: 17901641]

23 **Rock RB**, Sutherland WM, Baker C, Williams DN. Extrapulmonary Tuberculosis among Somalis in Minnesota. *Emerg Infect Dis* 2006; **12**: 1434-1436 [PMID: 17073097]

24 **Vinnard C**, Winston CA, Wileyto EP, Macgregor RR, Bisson GP. Isoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort study. *BMJ* 2010; **341**: c4451 [PMID: 20819874 DOI: 10.1136/bmj.c4451]

25 **Daikos GL**, Cleary T, Rodriguez A, Fischl MA. Multidrug-resistant tuberculous meningitis in patients with AIDS. *Int J Tuberc Lung Dis* 2003; **7**: 394-398 [PMID: 12729347]

26 **Centers for Diseases Control and Prevention**. CDC grand rounds: the TB/HIV syndemic. *MMWR* 2012; **61**: 484-489. [accessed 2015 Jan 5]. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6126a3.htm

27 **Torok ME**, Chau TT, Mai PP, Phong ND, Dung NT, Chuong LV, Lee SJ, Caws M, de Jong MD, Hien TT, Farrar JJ. Clinical and microbiological features of HIV-associated tuberculous meningitis in Vietnamese adults. *PLoS One* 2008; **3**: e1772 [PMID: 18350135 DOI: 10.1371/journal.pone.0001772]

28 **Caws M**, Thwaites G, Stepniewska K, Nguyen TN, Nguyen TH, Nguyen TP, Mai NT, Phan MD, Tran HL, Tran TH, van Soolingen D, Kremer K, Nguyen VV, Nguyen TC, Farrar J. Beijing genotype of Mycobacterium tuberculosis is significantly associated with human immunodeficiency virus infection and multidrug resistance in cases of tuberculous meningitis. *J Clin Microbiol* 2006; **44**: 3934-3939 [PMID: 16971650]

29 **Click ES**, Moonan PK, Winston CA, Cowan LS, Oeltmann JE. Relationship between Mycobacterium tuberculosis phylogenetic lineage and clinical site of tuberculosis. *Clin Infect Dis* 2012; **54**: 211-219 [PMID: 22198989 DOI: 10.1093/cid/cir788]

30 **Vyazovaya A**, Mokrousov I, Solovieva N, Mushkin A, Manicheva O, Vishnevsky B, Zhuravlev V, Narvskaya O. Tuberculous spondylitis in Russia and prominent role of multidrug-resistant clone Mycobacterium tuberculosis Beijing B0/W148. *Antimicrob Agents Chemother* 2015; **59**: 2349-2357 [PMID: 25645851 DOI: 10.1128/AAC.04221-14]

31 [**European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis**](http://www.ncbi.nlm.nih.gov/pubmed/?term=European%20Concerted%20Action%20on%20New%20Generation%20Genetic%20Markers%20and%20Techniques%20for%20the%20Epidemiology%20and%20Control%20of%20Tuberculosis%5BCorporate%20Author%5D). Beijing/W genotype Mycobacterium tuberculosis and drug resistance. *Emerg Infect Dis* 2006; **12**: 736-743 [PMID: 16704829]

32 **Sankar MM**, Singh J, Diana SC, Singh S. Molecular characterization of Mycobacterium tuberculosis isolates from North Indian patients with extrapulmonary tuberculosis. *Tuberculosis* (Edinb) 2013; **93**: 75-83 [PMID: 23140853 DOI: 10.1016/j.tube.2012.10.005]

33 **Rowińska-Zakrzewska E**. [Extrapulmonary tuberculosis, risk factors and incidence]. *Pneumonol Alergol Pol* 2011; **79**: 377-378 [PMID: 22028114]

34 **Delage G**, Dusseault M. Tuberculous meningitis in children: a retrospective study of 79 patients, with an analysis of prognostic factors. *Can Med Assoc J* 1979; **120**: 305-309 [PMID: 427668]

35 **Verdon R**, Chevret S, Laissy JP, Wolff M. Tuberculous meningitis in adults: review of 48 cases. *Clin Infect Dis* 1996; **22**: 982-988 [PMID: 8783697]

36 **Marx GE**, Chan ED. Tuberculous meningitis: diagnosis and treatment overview. *Tuberc Res Treat* 2011; **2011**: 798764 [PMID: 22567269 DOI: 10.1155/2011/798764]

37 **World Health Organization (Regional Office for Europe).** Surveillance report: Tuberculosis surveillance and monitoring in Europe 2012. [accessed 2015 Jan 5]. Available from: URL: http://ecdc.europa.eu/en/publications/Publications/1203-Annual-TB-Report.pdf

38 **Parimon T**, Spitters CE, Muangman N, Euathrongchit J, Oren E, Narita M. Unexpected pulmonary involvement in extrapulmonary tuberculosis patients. *Chest* 2008; **134**: 589-594 [PMID: 18641092 DOI: 10.1378/chest.08-0319]

39 **Herath S**, Lewis C. Pulmonary involvement in patients presenting with extra-pulmonary tuberculosis: thinking beyond a normal chest x-ray. *J Prim Health Care* 2014; **6**: 64-68 [PMID: 24624413]

40 **Smith I**. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. *Clin Microbiol Rev* 2003; **16**: 463-496 [PMID: 12857778]

41 **World Health Organization (Country Office for India)**. Standards for TB Care in India. [accessed 2015 Jan 5]. Available from: URL: http://www.tbcindia.nic.in/pdfs/stci%20Book\_Final%20%20060514.pdf

42 **Norbis L**, Alagna R, Tortoli E, Codecasa LR, Migliori GB, Cirillo DM. Challenges and perspectives in the diagnosis of extrapulmonary tuberculosis. *Expert Rev Anti Infect Ther* 2014; **12**: 633-647 [PMID: 24717112 DOI: 10.1586/14787210.2014.899900]

43 **Thwaites G**, Fisher M, Hemingway C, Scott G, Solomon T, Innes J. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. *J Infect* 2009; **59**: 167-187 [PMID: 19643501 DOI: 10.1016/j.jinf.2009.06.011]

44 **World Health Organization.** Policy update: Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system for the diagnosis of pulmonary and extrapulmonary TB in adults and children. [accessed 2015 Jan 5]. Available from: URL: http://apps.who.int/iris/bitstream/10665/112472/1/9789241506335\_eng.pdf

45 **Lew W**, Pai M, Oxlade O, Martin D, Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. *Ann Intern Med* 2008; **149**: 123-134 [PMID: 18626051]

46 **Croda MG**, Vidal JE, Hernández AV, Dal Molin T, Gualberto FA, de Oliveira AC. Tuberculous meningitis in HIV-infected patients in Brazil: clinical and laboratory characteristics and factors associated with mortality. *Int J Infect Dis* 2010; **14**: e586-e591 [PMID: 20005759 DOI: 10.1016/j.ijid.2009.08.012]

47 **Li L**, Zhang Z, Luo F, Xu J, Cheng P, Wu Z, Zhou Q, He Q, Dai F, Wang J, Zhang J. Management of drug-resistant spinal tuberculosis with a combination of surgery and individualised chemotherapy: a retrospective analysis of thirty-five patients. *Int Orthop* 2012; **36**: 277-283 [PMID: 22065055 DOI: 10.1007/s00264-011-1398-0]

48 **Pai M**, Nathavitharana R. Extrapulmonary tuberculosis: new diagnostics and new policies. *Indian J Chest Dis Allied Sci* 2014; **56**: 71-73 [PMID: 25230546]

49 **Cecchini D**, Ambrosioni J, Brezzo C, Corti M, Rybko A, Perez M, Poggi S, Ambroggi M. Tuberculous meningitis in HIV-infected patients: drug susceptibility and clinical outcome. *AIDS* 2007; **21**: 373-374 [PMID: 17255747 DOI: 10.1097/QAD.0b013e328012b84d]

50 **Lumb R**, Bastion I, Carter R, Jelfs P, Keehner T, Sievers A. Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2007. A report of the Australian Mycobacterium Reference Laboratory Network. *Commun Dis Intell Q Rep* 2009; **33**: 298-303 [PMID: 20043600]

51 **Afroz H**, Ali MA, Faruddin M, Kamrunnahar, Datta S. Prevalence and treatment follow-up of drug-resistant extra-pulmonary tuberculosis in rural communities in Narshingdi, Bangladesh. *Int J Advan Med* 2014; **1**: 71-77 [DOI: 10.5455/2349-3933.ijam20140801]

52 **Yang H**, Field SK, Fisher DA, Cowie RL. Tuberculosis in Calgary, Canada, 1995-2002: site of disease and drug susceptibility. *Int J Tuberc Lung Dis* 2005; **9**: 288-293 [PMID: 15786892]

53 **Xu L**, Jian-Zhong X, Xue-Mei L, Bao-Feng G. Drug susceptibility testing guided treatment for drug-resistant spinal tuberculosis: a retrospective analysis of 19 patients. *Int Surg* 2013; **98**: 175-180 [PMID: 23701156 DOI: 10.9738/INTSURG-D-12-00004.1]

54 **Duo L**, Ying B, Song X, Lu X, Ye Y, Fan H, Xin J, Wang L. Molecular profile of drug resistance in tuberculous meningitis from southwest china. *Clin Infect Dis* 2011; **53**: 1067-1073 [PMID: 22021920 DOI: 10.1093/cid/cir663]

55 **Christensen AS**, Andersen AB, Thomsen VO, Andersen PH, Johansen IS. Tuberculous meningitis in Denmark: a review of 50 cases. *BMC Infect Dis* 2011; **11**: 47 [PMID: 21342524 DOI: 10.1186/1471-2334-11-47]

56 **Biadglegne F**, Tessema B, Sack U, Rodloff AC. Drug resistance of Mycobacterium tuberculosis isolates from tuberculosis lymphadenitis patients in Ethiopia. *Indian J Med Res* 2014; **140**: 116-122 [PMID: 25222786]

57 **Jain A**, Dixit P, Jaiswal I, Garg RK, Kumar R. Drug resistance in mycobacterial isolates from meningitis cases. *Pediatr Infect Dis J* 2012; **31**: 1317 [PMID: 23188103 DOI: 10.1097/INF.0b013e3182717f25]

58 **Samant H**, Desai D, Abraham P, Joshi A, Gupta T, Rodrigues C, George S. Acid-fast bacilli culture positivity and drug resistance in abdominal tuberculosis in Mumbai, India. *Indian J Gastroenterol* 2014; **33**: 414-419 [PMID: 24927950 DOI: 10.1007/s12664-014-0467-x]

59 **Vadwai V**, Boehme C, Nabeta P, Shetty A, Alland D, Rodrigues C. Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis? *J Clin Microbiol* 2011; **49**: 2540-2545 [PMID: 21593262 DOI: 10.1128/JCM.02319-10]

60 **Desikan P**, Chauhan DS, Sharma P, Panwalkar N, Yadav P, Ohri BS. Clonal diversity and drug resistance in Mycobacterium tuberculosis isolated from extra-pulmonary samples in central India--a pilot study. *Indian J Med Microbiol* 2014; **32**: 434-437 [PMID: 25297032 DOI: 10.4103/0255-0857.142255]

61 **Baveja CP**, Gumma V, Jain M, Chaudhary M, Talukdar B, Sharma VK. Multi drug resistant tuberculous meningitis in pediatric age group. *Iranian J Pediatr* 2008; **18**: 309-314

62 **Nagarathna S**, Rafi W, Veenakumari HB, Mani R, Satishchandra P, Chandramuki A. Drug susceptibility profiling of tuberculous meningitis. *Int J Tuberc Lung Dis* 2008; **12**: 105-107 [PMID: 18173886]

63 **Pawar UM**, Kundnani V, Agashe V, Nene A, Nene A. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients. *Spine* (Phila Pa 1976) 2009; **34**: E806-E810 [PMID: 19829244 DOI: 10.1097/BRS.0b013e3181af7797]

64 **Tutkyshbaev S**, Amanzholova L. Multidrug resistance in patients with osteoarticular tuberculosis. *Med Health Sci J* 2011; **6**: 85-87 [DOI: 10.15208/mhsj.2010.114]

65 **Cho OH**, Park KH, Park SY, Moon SM, Chong YP, Kim MN, Lee SO, Choi SH, Woo JH, Kim YS, Kim SH. Drug-resistant extrapulmonary tuberculosis. *Infect Chemother* 2011; **43**: 258-261 [DOI: 10.3947/ic.2011.43.3.258]

66 **Gurung R**, Bhattacharya SK, Pradhan B, Gurung S, Singh YI. Phenotypic characterisation and drug sensitivity testing of mycobacteria isolated from extra-pulmonary tuberculosis. *Kathmandu Univ Med J* (KUMJ) 2010; **8**: 57-61 [PMID: 21209509 DOI: 10.3126/kumj.v8i1.3223]

67 **Butt T**, Kazmi SY, Ahmad RN, Mahmood A, Karamat KA, Anwar M. Frequency and antibiotic susceptibility pattern of mycobacterial isolates from extra-pulmonary tuberculosis cases. *J Pak Med Assoc* 2003; **53**: 328-332 [PMID: 14558735]

68 **Padayatchi N**, Bamber S, Dawood H, Bobat R. Multidrug-resistant tuberculous meningitis in children in Durban, South Africa. *Pediatr Infect Dis J* 2006; **25**: 147-150 [PMID: 16462292 DOI: 10.1097/01.inf.0000199314.88063.4c]

69 **Gunal S**, Yang Z, Agarwal M, Koroglu M, Arıcı ZK, Durmaz R. Demographic and microbial characteristics of extrapulmonary tuberculosis cases diagnosed in Malatya, Turkey, 2001-2007. *BMC Public Health* 2011; **11**: 154 [PMID: 21385458 DOI: 10.1186/1471-2458-11-154]

70 **Thwaites GE**, Lan NT, Dung NH, Quy HT, Oanh DT, Thoa NT, Hien NQ, Thuc NT, Hai NN, Bang ND, Lan NN, Duc NH, Tuan VN, Hiep CH, Chau TT, Mai PP, Dung NT, Stepniewska K, White NJ, Hien TT, Farrar JJ. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. *J Infect Dis* 2005; **192**: 79-88 [PMID: 15942897 DOI: 10.1086/430616]

**P- Reviewer:** Boonsarngsuk V, Garcia-Elorriaga G **S- Editor:** Gong XM

**L- Editor:** **E- Editor:**

**Table 1 Drug resistant-extrapulmonary tuberculosis: Reasons to worry**

|  |
| --- |
| Drug resistance (including MDR) in cases of EPTB is increasing and now it cannot be considered as rare |
| Accurate and timely diagnosis and drug susceptibility testing are very difficult and may result into high morbidity and mortality |
| DR-EPTB is often difficult to treatdue to poor penetration of **s**ome key anti-tubercular drugs into extra-pulmonary sites (especially in CSF) |
| HIV and young age are independent key risk factors |
| Although not contagious but it may co-exist with highly contagious pulmonary manifestation |

DR-EPTB: Drug resistant-extrapulmonary tuberculosis; CSF: Cerebrospinal fluid; HIV: Human immunodeficiency virus.

**Table 2 Drug resistant extrapulmonary tuberculosis in different parts of world**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Region** | **Type of EPTB** | **Study period** | **Culture positive cases/total cases analyzed** | **Prevalence of drug resistant MTB** | **DST method** | **Concomitant Pulmonary TB cases/total cases analyzed** | **HIV positive cases/total cases tested1** | **Treatment outcomes** | **Ref.** |
| Argentina | Tubercular Meningitis | 1996-2004 | 101 | Any DR: 51.5%  MDR: 41.6% | E | Not stated | 101/101 | 64/101 died during hospitalization | Cecchini *et al*[49] |
| Australia | Various sites (including pulmonary) | 2007 | 8712 (culture proven PTB/EPTB cases with available DST result) | MDR: 25% (6/24) of all MDR-TB cases | E | Not stated | Not stated | Not stated | Lumb *et al*[50] |
| Bangladesh | Various sites | 2011 | 152 (culture proven TB cases) | Any DR: 45.4%  MDR: 11.2 % | C | Not stated | Not stated | All cured | Afroz *et al*[51] |
| Brazil | Tubercular Meningitis | 1999-2007 | 108 (DST result available for 90 cases) | Any DR: 40%  MDR: 9% | D | Not stated | 108/108 | 31/108 died during hospitalization | Croda *et al*  [46] |
| Canada | Various sites | 1995-2002 | 126/214 | Any DR: 19%  INH-R: 7.9% | G | 0/214 | 4/126 | Not stated | Yang *et al*[52] |
| China | Spinal TB | 2005-2010 | 127/249  (35 DR cases studied in detail) | Any DR: 30.7% | A | 9/35 | 0/35 | No death;  33/35 cases cured | Li *et al*[47] |
| Spinal TB | 2006-2011 | 76/152  (19 DR cases studied in detail) | Any DR: 30.3% | A | Not stated | Not stated | No death;  19/19 cases cured | Xu *et al*[53] |
| Tubercular Meningitis | 2009-2010 | 30 (culture proven TB cases) | Any DR: 66.7%  MDR: 32.1% | B | 20/30 | 0/30 | Not stated | Duo *et al*[54] |
| Denmark | Tubercular Meningitis | 2000-2008 | 41/50 | INH-R: 4%  MDR: 2% | **D** | **23/50** | **5/50** | **9/50 cases died** | **Christensen *et al***[55] |
| Ethiopia | Tuberculosis lymphadenitis | 2012 | 225/437 | Any DR: 6.7%  MDR: 1.3% | D | Not stated | Not stated | Not stated | Biadglegne *et al*[56] |
| France | Various sites  (including pulmonary) | 1992-1999 | 264 MDR cases  (207 isolates from PTB cases, 19 isolates from EPTB cases and 38 from cases with both PTB and EPTB) | | D | 38/264 | 55/224 | Not stated | Robert *et al*[16] |
| India | Various EP sites | 2007-2010 | 227/756 (165 isolates confirmed as MTB) | Any DR: 39.9%  MDR: 13.5% | C | Not stated | 3/165 | Not stated | Maurya *et al*[18] |
| Tubercular Meningitis | Not stated | 51/370 | Any DR: 33.3%  MDR: 1.9% | D | Not stated | Not stated | Not stated | Jain *et al*[57] |
| Abdominal TB | 2008-2013 | 31/61  (DST analyzed for 18 isolates) | Any DR: 14.3%  MDR:5.4 % | A | 0/61 | 0/61 | Not stated | Samant *et al*[58] |
| Various EP sites | 2010 | 150/547  (14 cases excluded) | MDR: 33% | A | Not stated | 16/547 | Not stated | Vadwai *et al*[59] |
| Various EP sites | 2007-2011 | 125/419 | Any DR: 20.8%  MDR: 12% | A | Not stated | 7/125 | Not stated | Sankar *et al*[32] |
| Various EP sites | 2002-2006 | 338 (culture proven TB cases) | Any DR: 52.7%  MDR: 11.8 | D | Not stated | Not stated | Not stated | Sethi *et al* [19] |
| Various EP sites | 2010-2011 | 18 (culture proven TB cases) | MDR: 5% | D | Not stated | 0/18 | Not stated | Desikan *et al*[60] |
| Tubercular Meningitis | 2004-2005 | 22/100 | MDR: 18.2% | C | Not stated | 1/4 MDR cases | All 4 MDR cases died | Baveja *et al*[61] |
| Tubercular Meningitis | 2000-2003 | 256/2325  (DST analyzed for 205 isolates) | Any DR: 19%  MDR: 1.5% | C | Not stated | Not stated | Not stated | Venkataswamy *et al*[22] |
| Tubercular Meningitis | 2001-2005 | 366 (culture proven TB cases) | Any DR: 17.8%  MDR: 2.4% | C | Not Stated | 48/107 | Not Stated | Nagarathna *et al*[62] |
| Spine TB | 2004-2007 | 25 (culture proven MDR-TB cases) | | E | Not Stated | 2/25 MDR cases | 19/25 MDR-ETPB cases cured; rest 6 cases not concluded | Pawar *et al*[63] |
| **Kazakhstan** | Osteoarticular TB | 2007-2009 | 76/285 | MDR: 54.4% | I | Not stated | Not stated | Not stated | Tutkyshbaev and Amanzholova[64] |
| **Korea** | Various sites | 2008-2010 | 168 (culture proven TB cases) | Any DR: 8.9%  MDR: 1.8% | E | 52/168 (5 cases had DR-TB; 43 cases had disseminated TB) | 4/168 | Not stated | Cho *et al*[65] |
| Nepal | Various sites | 2004 | 54/513 (48 isolates confirmed as MTB) | Any DR: 62.9%  MDR: 12.6% | F | Not stated | Not stated | Not stated | Gurung *et al*[66] |
| Pakistan | Various sites | 2000-2002 | 98/460 (88 isolates confirmed as MTB) | MDR: 21.4% | H | Not stated | Not stated | Not stated | Butt *et al*[67] |
| Russia | Tuberculous spondylitis | 2008-2011 | 107 (culture proven TB cases) | DR: 75.7%  MDR: 69.1% | I | 66/107 | 25/107 (15 HIV cases had MDR) | Not stated | Vyazovaya *et al*[30] |
| South Africa | Tubercular Meningitis  (in children) | 1992 -2003 | 362/6781 | Any DR: 11.6%  MDR: 2% | E | Not stated | 6/8 MDR cases | 7/8 MDR cases died | Padayatchi *et al*[68] |
| Tubercular Meningitis | 1999 -2002 | 350/6762  (Only MDR cases studied) | MDR: 8.6% | E | 14/30 | 18/30 MDR cases | 17/30 MDR cases died (rest cases survived with disability) | Patel *et al*[20] |
| Taiwan | Various sites | 2000-2010 | 798 (culture proven TB cases) | Any DR: 15.5%  INH-R: 9.4%  MDR: 2.5% | D | Not stated | Not Stated | Not stated | Lai *et al*[17] |
| Turkey | Various EP sites | 2001-2007 | 103 (culture proven TB cases) | Any DR: 25.2% | A/C | Not stated | Unknown | Not stated | Gunal *et al*[69] |
| United States | Various sites | 1993 -2006 | 31633/47293 | MDR: 0.9% | E | Not stated | 4179/16888 | Not stated | Peto *et al*[13] |
| Pleural TB | 1993 -2003 | 4215/7549 | Any DR: 9.9%  INH-R: 6%; MDR: 1% | E | 264/7549 (sputum positive by culture) | 305/1378 | 679/7549 (9%) cases died during treatment | Baumann *et al*[15] |
| Various sites | 1993-2003 | 197/239  (in an ethnic group) | Any DR: 18%  MDR: 3% | D | 41/239 | 2/175 | One MDR case died; 169/186 (91%) cases completed treatment | Rock *et al*[23] |
| Tubercular Meningitis | 1993 -2005 | 1614/1896  (from CSF samples) | INH-R: 6% | E | 468/777 (sputum positive by culture) | 404/989 | 43/123 INH resistant cases died | Vinnard *et al*[24] |
| Vietnam | Tubercular Meningitis | 2004-2005 | 51/58 (DST result available for 46 cases) | Any DR: 54.3%  MDR: 8.7% | D | Not stated | 36/55 | 39/58 cases died; 11/58 cases survived; 8 cases lost to follow-up | Torok *et al*[27] |
| Tubercular Meningitis | 2001-2003 | 222 (culture proven TB cases) | Any DR: 35.1%  MDR: 4.1% | D | Not stated | 35/222 (17 HIV cases had DR-TB) | 24/35 TBM cases (HIV co-infected) died | Caws *et al*[28] |
| Tubercular Meningitis | 2000-2003 | 180 (culture proven TB cases) | Any DR: 40%  MDR: 5.6% | A | Not stated | 40/178  (21 HIV cases had DR-TB) | 60/180 cases (including 29 DR cases) died; 49/180 cases disabled; rest recovered well | Thwaites *et al*[70] |

Besides the reports tabulated here, some case studies as well as studies with very low sample size have also been reported from different countries but could not be addressed in this review. 1Cases with unknown HIV status are excluded from total number of cases tested; 2Isolates recovered from both pulmonary and extra-pulmonary sites. DST methods: A: BACTEC MGIT 960 system; B: PCR and Genotype MTBDR*plus* line-probe assay; C: BACTEC 460 TB system; D: Conventional DST using proportion method; E: Method not specified; F: Conventional DST using minimum inhibitory concentration method; G: Middlebrook 7H10 agar using proportion method; H: BacT/AlerT 3D system; I: Conventional DST using absolute concentration method. DR: Drug resistance to any one first line anti-tuberculosis drugs; MDR: Multi-drug resistance; DST: Drug susceptibility test; MGIT: Mycobacterial growth indicator tube; MTB: *Mycobacterium tuberculosis*; EPTB: Extra-pulmonary tuberculosis; PTB: Pulmonary tuberculosis; MIC: Minimum inhibitory concentration; INH: Isoniazid; HIV: Human immunodeficiency virus; R: Resistant; CSF: Cerebrospinal fluid; TBM: Tubercular meningitis; FNAs: Fine needle aspirates.

**Table 3 Key issues in diagnosis of drug resistant-extrapulmonary tuberculosis**

|  |
| --- |
| **Issues in laboratory diagnosis** |
| In general, the sensitivity of laboratory tests is often compromised  Due to pauci-bacillary nature of EPTB  Due to difficulty in obtaining an adequate sample |
| Risk associated with the sampling procedure (*e.g.*, lumbar puncture, biopsy of deep lymph nodes, *etc*.) |
| Lack of accessibility of serial samples for monitoring the treatment response |
| Un-availability of reliable host biomarkers that can be analyzed in easily attainable specimens |
| Xpert-MTB-RIF test seems promising diagnostic tool but the negative test result does not rule out EPTB and it can only determine the resistance to rifampicin (not other crucial drugs) |
| **Issues at programmatic/administrative level** |
| Lack of focused programme (like pulmonary TB) in many high TB burden countries |
| Lack of reliable estimates on impact and magnitude of DR-EPTB |
| Although seeking microbiological, histopathological diagnosis and drug susceptibility testing is crucial, it is however not in routine practice (in many high TB burden countries) |
| Rapid molecular based diagnostic (Xpert-MTB-RIF) is still away from its accessibility at peripheral health care centers in many resource limited countries |
| Wide variation in diagnostic and treatment practices among health service providers (as reported in private sectors of India) that often do not comply with national or international standards |

DR-EPTB: Drug resistant-extrapulmonary tuberculosis; MTB: *Mycobacterium tuberculosis*; RIF: Rifampicin.